Description of the medicine: Midantanum (Midantanum)
MIDANTAN (Midantanum). 1-aminoadamantane hydrochloride, or 1-adamantanamine hydrochloride.
Synonyms: Viregit, Adamantin, Amandin, Amantadini hydrochloridum, Amantadine hydrochoride, Amantan, Antadine, Atarin, Fluviatol, Gabirol, Mantadix, Mydantan, Paramentin, Protexin, Symmetrel, Viregit, Virofral, Virosol, etc.
White crystalline powder of bitter taste. Soluble in water, easy in alcohol.
The drug was originally proposed as an antiviral agent effective against type A 2 viruses. Its effectiveness in parkinsonism was subsequently discovered.
The mechanism of the therapeutic effect of midantan in parkinsonism is explained by the fact that it stimulates the release of dopamine from neuronal depots and increases the sensitivity of dopaminergic receptors to a mediator (dopamine); Thus, even with a decrease in the formation of dopamine in the basal ganglia, conditions are created for normalizing the neurophysiological processes that occur in them. There is also evidence that midantan inhibits the generation of impulses in the motor neurons of the central nervous system.
Midantan is used for Parkinson's disease and Parkinsinsonism of various etiologies. The drug is effective mainly in rigid and akinetic forms, less affects the hyperkinetic syndrome (tremor).
Information about the effectiveness of midantan as a corrector for antipsychotic syndrome is contradictory. According to some authors, the drug can be used for this purpose, according to others, its use is impractical, since in medium doses it is ineffective, and in large doses it can cause an exacerbation of psychopathological symptoms.
Midantan is a fast-acting drug, the effect usually occurs in the first days of treatment.
The drug can be prescribed independently and in combination with other antiparkinsonian drugs: anticholinergics and L-DOPA.
Midantan is prescribed orally after a meal. Take, starting from 0.05 - 0.1 g, first 2 times, then 3-4 times a day. Daily doses of 0.2 - 0.4 g. Duration of treatment 2 to 4 months.
The drug is usually well tolerated. In some cases, there may be headache, insomnia, dizziness, general weakness, dyspeptic symptoms. If necessary, reduce the dose.
Milantan is contraindicated in acute and chronic diseases of the liver and kidneys, as well as in 6 pregnancies. In connection with the possible excitation of the central nervous system, the drug should be prescribed with caution to patients with mental illness, with thyrotoxicosis, epilepsy.
Release form: tablets of 0.1 g, coated with a yellow shell, in a package of 100 pieces.
Storage: List B. In a dry place.
Rp.: Tab. Midantani 0.1 obd. N. 100